INTRODUCTION
The phosphorylation of proteins on tyrosyl residues is controlled by protein-tyrosine kinases (PTKs) (Lemmon and Schlessinger, 2010) and protein-tyrosine phosphatases (PTPs) (Alonso et al., 2004) , which direct diverse cellular processes, such as cell growth, proliferation, and migration (Tonks, 2006) . Aberrations in PTKs or PTPs contribute to several human diseases, including cancer (Julien et al., 2011; Lahiry et al., 2010) . A systems level understanding of cell signaling requires methods to identify PTKs and PTPs, determine their expression levels, and monitor their regulation. Most activated PTKs are phosphorylated on tyrosine and can be identified by phosphotyrosine (pY)-proteomics (Rikova et al., 2007; Zhang et al., 2005) . By contrast, proteomic approaches to assess PTP expression and regulation have lagged behind.
The PTP superfamily comprises 107 genes, divided into four families (Alonso et al., 2004) . The largest, the class I cysteinebased PTPs, can be subdivided into classical and dual-specificity PTPs (DUSPs). The classical PTP subfamily consists of 21 receptor and 17 nonreceptor PTPs that exclusively hydrolyze pY residues. Classical PTPs contain a conserved ''signature motif,'' [I/V]HCSXGXGR[S/T]G, within their active sites, wherein the invariant cysteine is essential for catalysis . Owing to its low pKa (4.5-5.5), the catalytic cysteine exists in the thiolate (S -) state at physiological pH (Zhang et al., 1994) . This property facilitates nucleophilic attack on substrate phosphotyrosines (Denu and Dixon, 1998) , but also renders PTPs highly susceptible to oxidation by reactive oxygen species (ROS) (Salmeen and Barford, 2005; Tanner et al., 2010) .
Although high levels of ROS damage cellular components, ROS, particularly H 2 O 2 , also function as intracellular second messengers [reviewed in Rhee et al., 2000; Tonks, 2005) ]. Early work showed that receptor tyrosine kinase (RTK) activation leads to transient H 2 O 2 production, which is required for full RTK phosphorylation and downstream signaling (Sundaresan et al., 1995) . PTPs were proposed as important ROS targets (Finkel, 1998) , and soon PTPN1 (PTP1B) was found to be reversibly oxidized and inactivated in response to EGFR activation (Lee et al., 1998) . Subsequently, studies have reported that oxidation of specific PTPs, including PTPN11 (SHP2) in PDGF signaling (Meng et al., 2002) , PTPN1 and PTPN2 (TC-PTP) in insulin signaling (Meng et al., 2004) , and PTPN6 (SHP1) in B cell receptor signaling (Singh et al., 2005) , is required for optimal responses to various stimuli.
Cancer cells often produce high levels of ROS (for review, see Cairns et al., 2011; Liou and Storz, 2010) , which could decrease basal PTP activity and enhance tyrosyl phosphorylation (Ostman et al., 2006) . Indeed, total PTP activity is decreased in BCR/ABL (Sattler et al., 2000) and Src (Gianni et al., 2008) transformed cells and can be restored by antioxidants or PTK inhibitors. Furthermore, overexpression of the ROS-producing protein Nox1 can cause cellular transformation and tumor formation (Arnold et al., 2001) , implicating excess ROS production in carcinogenesis.
The identification of ROS-inactivated PTPs might provide important clues to key PTPs that regulate normal and oncogenic signaling pathways. Yet while approaches to identify specific oxidized PTPs are available, it has been difficult to develop general methods that detect and quantify any reversibly oxidized PTP in different physiological and pathological contexts. A modified ingel phosphatase assay is currently the best global assay for PTP oxidation (Meng et al., 2002) , but this approach is biased toward nonreceptor PTPs (Burridge and Nelson, 1995) , is not quantitative, and requires the oxidized PTP(s) to be identified by immunodepletion. We exploited the biochemistry of PTP catalysis and oxidation and an available monoclonal antibody against ''hyperoxidized'' PTP active sites to develop global quantitative proteomic approaches that monitor classical PTP expression and oxidation.
RESULTS
Design of qPTPome and q-oxPTPome Assays H 2 O 2 promotes reversible oxidation of PTPs to the sulfenic acid (PTP-SOH) state (Rhee et al., 2000) , which is labile and, in different family members, rapidly rearranges to form a sulfenylamide with the adjacent main-chain nitrogen (Salmeen et al., 2003; van Montfort et al., 2003) or a disulfide bond to a nearby cysteine (Chen et al., 2009) . The sulfenylamide and disulfide states help limit ''hyperoxidation'' to the sulfinic (PTP-SO 2 H) and sulfonic (PTP-SO 3 H) acid states, which are biologically irreversible (Tonks, 2005) .
We exploited these biochemical properties to develop methods for quantifying classical PTP expression (qPTPome) and oxidation (q-oxPTPome), respectively (Figure 1A and Figure S1 available online) . Both methods use a monoclonal antibody (oxPTP Ab) raised against the signature motif of PTPN1 oxidized to the sulfonic acid (VHC SO3H SAG) (Persson et al., 2005) to isolate ''hyperoxidized'' PTPs (PTP-SO 3 H). This antibody has been used for immunoblotting of cell lysates and to monitor oxidation of specific PTPs Persson et al., 2004; Weibrecht et al., 2007) . Its precise reactivity had not been defined, but because the signature motif is highly conserved, we suspected (and found; see below) that the oxPTP Ab would react with most, if not all, classical PTPs.
Basal or ligand-induced PTP oxidation results in two pools of PTPs: oxidized (PTP-SOH; inactive) and reduced (PTP-S -; active). For q-oxPTPome, active PTPs are alkylated with N-ethylmaleimide (NEM; PTP-S-NEM), rendering them resistant to further modification, while oxidized PTPs remain unaffected (Figure 1A) . Excess NEM is removed by gel filtration, and reversibly oxidized PTPs are reduced with dithiothreitol (DTT). Following a buffer exchange, the reduced PTPs (representing PTPs that initially were reversibly oxidized), are oxidized to the sulfonic acid (PTP-SO 3 H) using pervanadate (PV) (Huyer et al., 1997) . For qPTPome, alkylation is omitted, and cells are lysed in the presence of DTT to reduce PTPs to the active (PTP-S -) state. Then, PTPs are ''hyperoxidized'' to the SO 3 H state and detected by immunoblotting with the oxPTP Ab or processed for mass spectrometry (MS). For MS, PV-treated lysates are digested with trypsin, and PTP-SO 3 H active site peptides are purified with the oxPTP Ab and identified (''discovery'' proteomics) by LC-MS/MS. Quantification can be achieved by various methods, including labeling with stable isotopes and/or chemical tags (for review, see Gstaiger and Aebersold, 2009; Walther and Mann, 2010; Yates et al., 2009) or, as follows, by selected reaction monitoring (SRM, also known as multiple reaction monitoring or MRM) (for review, see Elschenbroich and Kislinger, 2011) .
qPTPome Reliably Identifies Classical PTPs For qPTPome, NIH 3T3 cells were lysed in the presence of DTT, followed by a buffer exchange and treatment with PV. Multiple bands were detected in immunoblots with the oxPTP Ab in PVtreated, compared with untreated, lysates ( Figure 1B ). Next, native or denatured PV-treated lysates were immunoprecipitated and immunoblotted with the oxPTP Ab ( Figure 1C ). Again, new bands were detected in the PV-treated lysates ( Figure 1C , compare lanes 5 and 6). Denaturing the lysate prior to immunoprecipitation increased recovery of oxidized PTPs ( Figure 1C , compare lanes 4 and 6), suggesting that the epitope for the oxPTP Ab is not very accessible in the native PTP-SO 3 H conformation. As expected, NEM treatment prior to reduction markedly decreased oxPTP Ab-immunoreactive bands ( Figure 1C , lanes 3 and 5). We also immunoblotted oxPTP and anti-Ptpn11 immunoprecipitates from denatured lysates with anti-Ptpn11 antibodies. Similar levels of Ptpn11 were recovered in each immunoprecipitate, suggesting that immunoprecipitation by the oxPTP Ab was quantitative ( Figure 1C , compare lanes 2 and 6).
To identify the PV-inducible species, cell extracts were digested with trypsin, and peptides immunopurified with the oxPTP Ab were analyzed by LC-MS/MS. These experiments revealed active site PTP-SO 3 H peptides from 17 classical PTPs ( Figure 1D ). Importantly, unlike the in-gel PTPase approach (see Introduction), qPTPome detected the D1 and D2 domains from several RPTPs (Ptpra, Ptpre, Ptprf, and Ptprs). Nearcomplete overlap in PTP expression was observed in biological replicates using NIH 3T3 cells ( Figure 1E ) and other cell lines and tissues (see Figure S2A) .
To determine the range of classical PTPs that could be detected, we performed qPTPome on tissues from C57BL/6J mice ( Figure 2A Table S1, and Table S2 ), several human cell lines ( Figure 2B , and Table S1, and Table S2 ) and the rat basophilic leukemia line RBL2H3 ( Figure S2B , Table S1 , and Table S2 ). Nearly all classical PTPs (17/17 nonreceptor and 19/21 RPTPs) were identified, and PTPs accounted for $70% of the Cys-SO 3 H-containing proteins recovered in these experiments (Table  S1) . Notably, members of other phosphatase families (e.g., DUSPs) were not detected, indicating that the oxPTP Ab is highly specific for the classical PTP signature motif. Other recovered peptides had sequence similarity to this motif (see below) or were from abundant proteins (Table S1) .
Each cell line and tissue had a unique PTP profile. For example, PTPN1 and PTPN2 were expressed ubiquitously, whereas PTPRC and PTPRD were present more selectively.
There was near-complete overlap between PTPs identified by qPTPome and in published microarray analyses ( Figure 2C and Table S1 ), providing further evidence of the reliability of our assay. This correlation was not absolute, though, indicating that posttranscriptional mechanisms contribute significantly to determining PTP protein levels.
We also applied our method to a cell type with an unknown PTP expression profile. Platelets are anuclear and express only small amounts of residual megakaryocyte mRNA, making it difficult to define their PTPome by RNA-based approaches.
Using qPTPome, we identified 16 PTPs in platelets ( Figure 2D ), including PTPN2, PTPRA, and PTPRE, which had not been identified previously. When antibodies were available, these identifications were confirmed by immunoblotting ( Figure S2C ). Figure S2 and Tables S1 and S2.
The above data set allowed us to define the specificity of the oxPTP Ab. We aligned the sequences of the tryptic peptides from the active sites of all classical PTPs, highlighting those detected by qPTPome ( Figure 2E and Figure S2D ). Although the D1 domains of Ptprc, Ptprm, Ptprk, Ptprt, and Ptpru were identified, their D2 domains, which cluster at the top of the multiple sequence alignment, were not. The active site sequences of these D2 domains (VHCRDG and [I/V]HCLNG) diverge substantially from the sequence used to generate the oxPTP Ab. To ask if the oxPTP Ab could recognize these sequences, we performed immunoprecipitations with synthetic PTP-SO 3 H peptides. As expected, the oxPTP Ab isolated the Ptpn1 peptide, but not the D2 domains of Ptprk, Ptprm, Ptprt, and Ptpru (data not shown). These experiments suggested that the oxPTP Ab recognizes [I/V]HC SO3H S[A/S]G, and that, given their divergent active sites, Ptprn (VHCSDG) and Ptprn2 (VHCSDG) also would not be detectable. Notably, Ptprn and Ptprn2 are catalytically inactive (Gross et al., 2002) ; hence, qPTPome can identify all catalytically active classical PTPs in a single MS experiment.
Quantification of the PTPome
Selected reaction monitoring (SRM) is a label-free method that determines the relative abundance of peptide ions by measuring signals associated with specifically defined, distinctive, coeluting parent ion-to-product ion transitions (Picotti et al., 2009 ). We developed a multiplexed SRM (mSRM) protocol to quantify the classical PTPome or oxPTPome from human, mouse, or rat ( Figure S3A ). Following enrichment by the oxPTP Ab, PTP peptide ions and their product ion fragments first were observed in ''discovery mode'' LC-MS/MS, and then SRM transitions for each PTP were designed, optimized, and combined into a single mSRM protocol (Table S3 ). The optimized mSRM transitions were validated for several ($50%) mouse and human PTPs using synthetic peptides (Table S3) . Furthermore, all active site peptides from classical PTPs in NIH 3T3 ( Figure S3B ) and A431 ( Figure S3C ) cells were immunodepleted by the oxPTP Ab, demonstrating that the assay is quantitative.
Next, we assayed Ptpn11 fl/KO fibroblasts ( Figure 3A ), in which 4-hydroxytamoxifen (4-OHT) addition activates a Cre-ER fusion protein and evokes deletion of a floxed Ptpn11 allele (Ptpn11 KO/KO ). Notably, the Ptpn11 signal from 4-OHT-treated cells was much lower than from controls, whereas their Ptpn1 signals were similar ( Figure 3B ). Moreover, the SRM signals paralleled the respective Ptpn11 and Ptpn1 levels detected by immunoblotting ( Figure 3C ). To display the mSRM signals for all PTPs simultaneously, we developed a heat map representation ( Figure 3D and Figure 3E ); by contrast, Ptpn1 expression remained similar. These findings agreed with a global immunoblot using the oxPTP Ab ( Figure 3F ) and with RT-PCR measurements of Ptprd mRNA ( Figure 3G ). Also consistent with the oxPTP immunoblot, there were no significant changes in classical PTP expression aside from Ptprd in these samples ( Figure 3H and Table S3 ).
As implemented above, qPTPome displays the relative level of each classical PTP. We asked if, by combining qPTPome with absolute quantification (AQUA) (Gerber et al., 2003) , the absolute amount of a PTP could be determined ( Figure S1 ). We synthesized a Ptpn11-SO 3 H active site tryptic peptide containing a ''heavy'' arginine (six 13 C and four 15 N). Using a standard curve generated with this peptide (Figure 3I ), we found that our SRM assay is linear over at least three orders of magnitude. By comparing the intensities of coeluting ''heavy'' (AQUA) and ''light'' (endogenous) Ptpn11-SO 3 H peaks recovered by the oxPTP Ab ( Figure 3J ) and assuming complete digestion with trypsin, we determined that there are $32,000 copies of Ptpn11 in each NIH 3T3 cell. This measurement compares well (within 4-fold) with immunoblot determinations ( Figure S3D ).
Quantification of the PTP ''Redoxome'' Next, we attempted to quantify PTP oxidation ( Figure 4A ). NIH 3T3 cells were stimulated with increasing concentrations of H 2 O 2 for 5 min and analyzed by q-oxPTPome. In parallel, qPTPome measurements were obtained to assess the stoichiometry of PTP oxidation. Under these conditions, the Ptpn6 and Ptpn11 SRM profiles showed dose-dependent, but differential increases in oxidation ( Figure 4A ), which were confirmed by immunoblotting ( Figure 4B ). We used a heat map to display the oxidized proportion of each PTP relative to its total amount (q-oxPTPome/qPTPome; Figure 4C and Table S4 ). As expected, under normal growth conditions, most PTPs had very low levels of basal oxidation to the PTP-SOH or SO 3 H states. By contrast, Ptpn23, Ptpra D2, Ptprf D2, and Ptprk D1 had high basal oxidation. With the exception of Ptprk D1, these PTP domains reportedly are catalytically inactive (Gingras et al., 2009; Persson et al., 2004) . The D1 and D2 domains of specific RPTPs showed clear differences in oxidation sensitivity. For example, Ptpra D1 had a low level of oxidation, while its D2 domain was highly oxidized. By contrast, Ptprs D1 and D2 both showed low basal oxidation. As expected, increasing the H 2 O 2 concentration increased the oxidation of multiple PTPs, including Ptpn1, Ptpn3, Ptpn9, and Ptpra D1 ( Figure 4C) . Surprisingly, though, Ptpn23 and Ptpra D2 oxidation appeared to decrease.
We suspected that this might reflect oxidation to the SO 2 H state, which should not be converted to the SO 3 H state by PV (Huyer et al., 1997 ) and hence would not be recognized by SRM. To test this possibility, we modified the q-oxPTPome protocol ( Figure 4D ; see Experimental Procedures for details) to enable identification and quantification of all PTP oxidation states (S -, SOH, SO 2 H, SO 3 H). Not surprisingly, most PTPs were oxidized by 10 mM H 2 O 2 ( Figure 4E and Table S4 ). Yet while several PTPs were converted to the SO 2 H state, including Ptpn23 and Ptpra D2, very few were converted to the SO 3 H state. Hence, extremely high levels of oxidative stress are required to completely oxidize PTPs inside cells. Most other PTPs, including Ptpn11 and Ptprs D1, showed high levels of reversible oxidation (PTP-SOH), whereas a few remained reduced. We next assessed the changes in PTP oxidation caused by exposure of NIH 3T3 cells to buthionine sulphoximine (BSO), which inhibits glutathione synthesis. As expected, intracellular ROS levels increased ( Figure 4F ), and concomitantly, several PTPs showed increased oxidation ( Figure 4G and Table S4 ). Interestingly, although PTP oxidation levels were similar in BSOtreated and H 2 O 2 (1 mM)-stimulated cells, the profile of oxidized PTPs differed significantly (compare Figures 4C and 4G ).
Quantifying PTP Nitrosylation
PTPs also can be regulated by reversible nitrosylation of their active site cysteines. Targeted indirect approaches have been used to detect nitrosylation of a few PTPs, including PTPN1 and PTPN11 (Li and Whorton, 2003) . To see if our method could monitor PTP nitrosylation, NIH 3T3 cells were exposed to three different nitrosylating agents, processed and analyzed by q-oxPTPome. We detected nitrosylation of several PTPs (Figure 4H and Table S4 ), including Ptpn1 and Ptpn11 (Hsu and Meng, 2010; Li and Whorton, 2003) . Consistent with the q-oxPTPome signals arising from nitrosylation, not oxidation, SRM signals for Ptpn23 and Ptpra D2 did not decrease ( Figure 4H ), and ROS levels remained unchanged (data not shown) in cells exposed to these agents.
Application of qPTPome and q-oxPTPome to Cancer Cells ROS levels often increase in cancer (Liou and Storz, 2010) . Although increased oxidation of individual PTPs has been reported in selected cancer cell lines (Lou et al., 2008) , the global effects of excess ROS on PTP oxidation have not been assessed. As a proof of principle, we analyzed A431 ( Figure 5A and Table S5 ) and NIH 3T3 cells transformed with constitutively active Src (Src Y527F; Figure 5B and Table S5 ). Many PTPs were reversibly oxidized in both lines, with generally higher levels of oxidation in A431 cells. Notably, we detected $20% oxidation of PTPN1 in A431 cells, remarkably similar to the 25% oxidation determined using a targeted MS method (Lou et al., 2008) .
We compared PTP oxidation in A431 and Src Y527F cells with that in cell lines derived from several types of cancer (Figures 5C  and 5D and Table S5 ). Global PTP oxidation was higher in Src Y527F cells, compared with nontransformed NIH 3T3 cells. A431 and H1975 cells showed the highest levels of PTP oxidation and the highest levels of intracellular ROS ( Figures S4B  and S4C ). Some PTP domains (e.g., PTPRA D2, PTPN23) were highly oxidized in all cancer cells tested; others (e.g., PTPN1, PTPN11) had lower and variable levels of basal oxidation in these cell lines.
We then compared PTP oxidation in six HER2+ breast cancer cell lines. Although some PTPs were differentially oxidized (Figures 5E and 5F and Table S5 ), there was less heterogeneity between these lines than between lines derived from different types of cancer (compare Figures 5C and 5E ). Also, while there were some general trends in relative oxidation levels, each cancer line contained a unique profile of oxidized PTPs. Notably, the ROS levels in a given cell line and the extent of PTP oxidation did not correlate strongly (compare Figure 5 and Figures S4B and S4D) .
To ask if PTP oxidation was controlled by a mutant PTK, we treated SrcY527F cells with the Src kinase inhibitor, PP2. Global tyrosyl phosphorylation ( Figure 6A ) and ROS ( Figure 6B ) levels decreased following PP2 treatment, accompanied by an overall decrease in PTP oxidation ( Figure 6C and Table S6 ). Nevertheless, some PTPs, (e.g., Ptpn3 and Ptpra D2) remained oxidized following PP2 treatment.
Combining qPTPome with Phosphotyrosine Proteomics to Suggest PTP Substrates Finally, we asked if combining qPTPome with pY-proteomics could suggest PTP/substrate relationships. We used qPTPome to quantify PTP expression in several multiple myeloma (MM) cell lines ( Figure 7A and Table S7 ) and measured 93 unique pY sites in the same cells by pY-proteomics ( Figure 7B and Table S7 ). Using partial least-squares regression (PLSR) analysis, we sought relationships between the levels of various pY-peptides and the expression of specific PTPs (see Experimental Procedures for details). The resultant model predicted relative pY-peptide levels well ( Figure 7C and Table S7), with Component 1 accounting for 97% of the variance and Component 2 explaining another 2%. PTPN1 levels correlated most strongly with Component 1, with PTPN6 and PTPN11 also contributing significantly. PTPN7 explained most of the variation in Component 2, and contributed to Component 1.
Overall, PTPN1, PTPN6, PTPN7, and PTPN11 levels could explain the majority of the variation for many of the pY sites analyzed. Interestingly, the site best explained by the first two components was from TYK2 (Table S7) , a known PTP1B substrate (Myers et al., 2001) . The relative pY levels of the FGFR3 activation loop phosphotyrosyl residue also were highly correlated with Components 1 and 2 (Table S7) . Surprisingly, these correlations were positive: peptide phosphorylation increased as the PTP expression level increased (Table S7) . Nevertheless, given the prominent role of PTPN1 in regulating tyrosyl phosphorylation of several other RTKs (Bourdeau et al., 2005) , we tested the effects of a PTPN1 shRNA on one of these lines (KMS11). Remarkably, PTPN1 depletion led to increased tyrosyl phosphorylation of FGFR3 and several other proteins, including one with the molecular weight of TYK2 ( Figure 7D ). These data suggest that, like TYK2, FGFR3 is probably a bona fide in vivo target of PTPN1.
DISCUSSION
By using proteomic methods that enable comprehensive analysis of the classical PTPome ( Figure 1A) , we identified the PTPs in multiple human, mouse, and rat cell lines and tissues (Figure 2 ), including platelets ( Figure 2D ), cells in which RNAbased approaches have been of limited benefit. Our studies uncover significant posttranslational regulation of PTP levels ( Figure 2C ) and unanticipated complexity in PTP oxidation evoked by exogenous and endogenous ROS in normal and neoplastic cells (Figures 4-6 ). Such differential PTP oxidation represents a new layer of complexity in signal transduction. Furthermore, combining our assay with pY-proteomics can help to identify PTP substrates (Figure 7) . We used SRM to quantify PTP expression because it is easily applied to tissues and cell lines, but our assay also accommodates other quantification methods (Yates et al., 2009) . Additional variations could permit simultaneous identification of posttranslational modifications ( Figure S1 ): e.g., the oxPTP Ab could be used to isolate full-length (denatured) PTPs, and phosphorylated tryptic peptides could be recovered (with TiO 2 or anti-pY antibodies), followed by MS. The oxPTP Ab does not detect DUSPs, but by using more degenerate anti-Cys-SO 3 H hapten antibodies, analogous approaches could monitor oxidation (and expression) of these (and other) cysteinyl proteins ( Figure S1 ).
The lack of global methods to identify oxidized PTPs has hampered progress on redox regulation. Several other indirect approaches use an overall strategy similar to q-oxPTPome. The modified in-gel PTPase assay (Meng et al., 2002) has been the most successful, but it relies on immunodepletion for PTP identification, rarely detects RPTPs and is not quantitative. The modified cysteinyl-labeling assay isolates oxidized PTPs using iodoacetylpolyethylene oxide biotin (IAP-Biotin) (Boivin et al., 2010) or activity-based probes, such as a-bromobenzylphosphonate biotin (BBP-Biotin) (Kumar et al., 2004) . Direct approaches using dimedone, which reacts selectively with SOH groups, represent a promising alternative (Poole and Nelson, 2008) . Biotin-coupled dimedone probes (Nelson et al., 2010) and dimedone-specific antibodies (Seo and Carroll, 2009 ) are available. However, none of these approaches have been developed into a global MS assay for PTP oxidation. Recently, a modified IAP-Biotin probe was used to identify reactive cysteinyl residues by MS (Weerapana et al., 2010) , but only three PTP-derived peptides were detected (from >1000 cysteine-containing species), and none corresponded to active site peptides. The high reactivity of IAP-Biotin with any reactive S -probably increases the background of abundant (non-PTP) proteins, which also could be problematic for dimedone-based approaches. These limitations are surmounted by q-oxPTPome, which uses a highly specific antibody to purify PTPs. Notably, q-oxPTPome cannot yet identify the PTPs oxidized upon growth factor (E) Basal PTP oxidation in HER2+ breast cancer lines measured by q-oxPTPome (n = 2; two technical replicates each).
(F) Same as (E), but with scale altered to show PTPs that were oxidized to lower extents. Also, see Figure S4 and Table S5 . Table S7. stimulation, probably because only a small subset of PTPs is inactivated (under steady state conditions) by growth factorevoked ROS (e.g., see den Rhee et al., 2000; Woo et al., 2010) . Similar obstacles confronted initial phosphoproteomic (including pY-proteomic) methods, prior to secondary enrichment strategies (Ahn et al., 2007; Pandey et al., 2002) . Our results add to growing evidence that ROS production and PTP oxidation are highly controlled in cells (Li et al., 2006; Woo et al., 2010) . First, because our assay is quantitative, we can provide an upper bound on growth factor-induced increases in PTP oxidation (<5%). For such a small change to impact signaling (see Introduction), local control would be essential. Consistent with in vitro studies Weibrecht et al., 2007) , we find that PTPs also differ in relative oxidation sensitivity in cells. Surprisingly, though, the pattern of oxidized PTPs in cells stimulated by exogenous H 2 O 2 differs from that evoked by increasing endogenous H 2 O 2 levels (Figure 4) . Furthermore, different cancer cells have distinct PTP oxidation profiles ( Figure 5 ) that do not simply correlate with global ROS levels ( Figure S4 ), again consistent with the idea that local ROS alterations are critical for altering tyrosyl phosphorylation events. Interestingly, transformation can have fairly durable effects on redox homeostasis, as oxidation of some PTPs cannot be reversed readily by oncogene inhibition (Figure 6 ). Further analyses of this phenomenon might shed light on key regulators of local ROS production/redox regulation.
Finally, qPTPome can be combined with pY-proteomics to suggest specific PTP substrates (Figure 7) . We identified four PTPs that appeared to play a key role in regulating phosphotyrosyl protein homeostasis in MM cells. Two of these PTPs have been implicated in MM: PTPN6 is reportedly a tumor suppressor, whereas PTPN7 is overexpressed (Julien et al., 2011) . PTPN11 is a known positive regulator of the RAS-MAPK pathway and is a bona fide oncogene (Chan et al., 2008) . Although PTPN11 has not been implicated specifically in MM, it is required for the transformation of NIH 3T3 cells expressing oncogenic FGFR3 (Agazie et al., 2003) , a common MM oncogene. Moreover, PTPN1 depletion in KMS11 cells leads to FGFR3 hyperphosphorylation and increased global phosphotyrosine levels ( Figure 7D ), suggesting that PTPN1 may be a key negative regulator of FGFR3. Unexpectedly, expression of PTPN1 (and the other three PTPs) correlates positively with tyrosyl phosphorylation of several peptides, yet knockdown causes increased phosphorylation of the same species. Conceivably, these apparently paradoxical findings reflect an attempt by MM cells to limit the effects of excess FGFR3 signaling by upregulating its negative regulators.
In any case, our results argue strongly that altered redox regulation provides an additional level of complexity to the cancer phenotype. Further refinement and application of qPTPome and q-oxPTPome should help delineate the contribution of ROS regulation of PTPs to normal and pathological cell signaling.
EXPERIMENTAL PROCEDURES Cells and Viral Infection
Cell lines were cultured under standard conditions and treated with H 2 O 2 (Bioshop) for 5 min or 100 mM BSO (Sigma) for 24 hr, as indicated. Nitrosylation was induced by exposing cells for 30 min to 0.5 mM SNAP (Calbiochem) and L-cysteine (Sigma), GSNO (Alexis Biochemicals) and L-cysteine or CSNO (Sigma), each prepared as described (Li and Whorton, 2003 
ROS Levels
Cells (80% confluence) were serum-starved overnight and treated as indicated. Plates were washed with PBS (23), trypsinized, incubated for 5 min with 300 nM DCF-DA (Invitrogen) at 37 C and washed immediately with ice-cold PBS (33). Mean fluorescence intensity (MFI) was quantified by flow cytometry (FACs Calibur).
qPTPome Cells or tissues were homogenized in 50 mM HEPES (pH 7.4), 150 mM NaCl, 10% glycerol, 1% NP40, containing 10 mM DTT and a protease and phosphatase inhibitor cocktail. Lysates were clarified at 16,100 3 g for 15 min at 4 C.
Supernatants were rotated in the dark at room temperature (RT) for 30 min., desalted by gel filtration into 20 mM HEPES (pH 7.4), treated with 100 mM PV (Huyer et al., 1997) , and rotated at 4 C for 1 hr in the dark. Proteins were denatured in SDS (0.5%) and EDTA (5 mM) at 95 C for 5 min, diluted 5-fold into NP40
buffer (20 mM Tris-HCl [pH 8.0], 137 mM NaCl, 10% glycerol, 1% NP-40, 2 mM EDTA) and immunoprecipitated overnight at 4 C with the oxPTP Ab (mouse monoclonal anti-oxidized PTP active site antibody, clone 335636 [R&D Systems]; 5 mg Ab/mg protein) and 40 ml of packed protein G Sepharose beads. For MS, samples were incubated in 9M urea/4.5 mM DTT at 60 C for 30 min, cooled to RT, treated with 10 mM iodoacetamide (IAM) for 15 min in the dark, diluted to a final concentration of 2 M urea, 20 mM HEPES (pH 8.0), and digested overnight at RT in 10 mg/ml TPCK-trypsin (Pierce). IAM prevents incomplete digestion due to disulfide bonds and ensures alkylation of other cysteines (besides the catalytic cysteine) found in some PTP active site peptides. Peptides were purified on a C18 column (Waters) by following the manufacturer's instructions, lyophilized, resuspended in 1.4 ml peptide IP buffer (50 mM HEPES [pH 7.4], 50 mM NaCl) and incubated for 30 min on a shaker at RT. Insoluble matter was removed by centrifugation at 2000 3 g. Supernatants were collected, and PTP-SO 3 H active site peptides were isolated by immunoprecipitation with the oxPTP Ab. Immunoprecipitates were washed in 1 ml peptide IP buffer (33), followed by 1 ml HPLC grade H 2 O (33), eluted by incubating with 80 ml 0.15% trifluoroacetic acid for 10 min at RT (33), dried, and analyzed by MS. The Ptpn11 AQUA peptide (QESIVDAGPVVVHC SO3H SAGIGR; six 13 C and four 15 N) was purchased from Thermo Scientific.
q-oxPTPome q-oxPTPome buffer (50 mM HEPES [pH 6.5], 150 mM NaCl, 10% glycerol, 1% NP40) was degassed overnight at 30-35 mmHg, transferred into a sealed round-bottom flask equilibrated with N 2 , purged with N 2 for 1 hr, transferred to an anaerobic workstation (ESBE Invivo 2 400), and treated with 10 mM NEM (Sigma), 100 mg/ml catalase (Calbiochem) and a protease and phosphatase inhibitor cocktail. Cells were washed with ice-cold degassed PBS, transferred to the workstation and lysed in q-oxPTPome buffer. Lysates were incubated for 1 hr at 4 C in the dark, and homogenates were clarified at 16,100 3 g for 15 min at 4 C. Supernatants were collected in the anaerobic workstation, and the buffer exchanged by gel filtration into degassed 20 mM HEPES (pH 7.4). Desalted lysates were treated with 10 mM DTT and rotated in the dark for 30 min at RT. After exchanging the buffer to remove DTT, samples were treated with 100 mM PV, rotated at 4 C for 1 hr in the dark and analyzed by immunoprecipitation or MS. The DTT step is included to reduce all reversibly oxidized PTPs; omitting this step prevents PV from accessing the PTP active site and limits PTP oxidation to the SO 3 H state.
Measurement of all PTP Oxidation States
The total signal for each PTP is provided by qPTPome, while q-oxPTPome determines the cumulative fraction of each PTP in the SOH and SO 3 H states. Figure 4D ).
LC-MS/MS
LC-MS, peptide identification, and SRM were performed by using standard techniques and procedures. Samples were prepared for pY-proteomics as described (St-Germain et al., 2009) . See Supplemental Information for details.
Statistical Analysis
Data are presented as the mean ± SEM. Statistical significance was determined using Student's t test (paired or unpaired) or one-way ANOVA, as appropriate. If ANOVA was significant, individual differences were evaluated using Bonferroni post-test. Statistical analyses were performed using GraphPad Prism 5, with p < 0.05 considered significant. Given the multivariate multiple linear regression problem: Y = XB+ε (1), where X is an I x K predictor matrix of PTPs and Y is an I x J response matrix of pY sites with both X and Y measured in five (I) different MM cell lines, PLSR was implemented in the R (version 1.40) package PLS (Mevik and Wehrens, 2007) to fit a solution to (1) using the NIPALS algorithm. PLSR attempts to predict Y from X and describe their common structure by simultaneously decomposing the predictor and response variables into a common set of orthogonal factors and specific loadings: X = TP T ; Y = UC T $ = TBC T , where T is the score matrix, P is the loading matrix, B is a diagonal matrix of regression weights, and C is a weight matrix. T and U are chosen such that their covariance is maximal. ''Leave-one-out'' cross-validation was used to determine the optimal number of components to use in the regression. Prior to fitting the model, we excluded those PTPs and pY sites where there were two or fewer measurements across the five cell lines.
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